Scholarlink

Background <p>Atezolizumab (A) plus carboplatin-etoposide (CE) represents the new first-line treatment in extensive stage (ES)-Small Cell Lung Cancer (SCLC) patients. This study aims at identifying the association of baseline and dynamic changes of cfDNA, Tumor Fraction (TF) and variant allele frequency (VAF) of tumor-related mutations with median (m) overall (OS) and progression free survival (PFS) in SCLC patients treated with ACE.</p> Materials and methods <p>This is a single-center prospective exploratory study including treatment-naive ES-SCLC patients eligible to first-line ACE. Liquid biopsies were longitudinally collected at baseline (T0), after cycle 1 (T1) and 2 (T2), at disease progression (T3). cfDNA Next Generation Sequencing (NGS) analysis was performed; genomic profiles and TF were inferred from shallow WGS (sWGS).</p> Results <p>Thirty-two patients were included; mPFS and mOS were 5.19 and 7.96 months, respectively. Higher T0 cfDNA (HR 1.44, 95% CI 1.17–1.77, <i>p</i> = 0.0006) and VAF (HR 2.6, 95% CI 1.36–4.93, <i>p</i> = 0.0039) were associated with risk of death; higher T0 cfDNA (HR 1.29, 95% CI 1.08–1.54, <i>p</i> = 0.0049), TF (HR 1.97, 95% CI 1.02–3.82, <i>p</i> = 0.044) and VAF (HR 2.32, 95% CI 1.22–4.42, <i>p</i> = 0.01) were predictors of risk of PD. Among the dynamic changes in the biomarkers under investigation, the association of 10-unit increase of VAF T0-T1 and T0-T2 with OS (HR 1.38, 95% CI 1.01–1.88, <i>p</i> = 0.043; HR 1.56, 95% CI 1.21–2.16, <i>p</i> = 0.008) and PFS (HR 1.69, 95% CI 1.18–2.43, <i>p</i> = 0.004; HR 1.81, 95% CI 1.22–2.70, <i>p</i> = 0.003) was estimated.</p> Conclusion <p>T0 and dynamic changes of cfDNA, TF and VAF may help physicians to stratify ES-SCLC patients receiving first-line ACE and to anticipate the clinical course of the disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS/ML43257)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月19日

查看全文
  • Giulia Pasello,
  • Giulia Pigato,
  • Daniela Scattolin,
  • Stefania Lando,
  • Sara Potente,
  • Chiara Romualdi,
  • Anna Roma,
  • Maria Vittoria Resi,
  • Stefano Frega,
  • Alessandra Ferro,
  • Alessandro Dal Maso,
  • Laura Bonanno,
  • Valentina Guarneri,
  • Elisabetta Lazzarini,
  • Stefano Indraccolo

摘要

Background

Atezolizumab (A) plus carboplatin-etoposide (CE) represents the new first-line treatment in extensive stage (ES)-Small Cell Lung Cancer (SCLC) patients. This study aims at identifying the association of baseline and dynamic changes of cfDNA, Tumor Fraction (TF) and variant allele frequency (VAF) of tumor-related mutations with median (m) overall (OS) and progression free survival (PFS) in SCLC patients treated with ACE.

Materials and methods

This is a single-center prospective exploratory study including treatment-naive ES-SCLC patients eligible to first-line ACE. Liquid biopsies were longitudinally collected at baseline (T0), after cycle 1 (T1) and 2 (T2), at disease progression (T3). cfDNA Next Generation Sequencing (NGS) analysis was performed; genomic profiles and TF were inferred from shallow WGS (sWGS).

Results

Thirty-two patients were included; mPFS and mOS were 5.19 and 7.96 months, respectively. Higher T0 cfDNA (HR 1.44, 95% CI 1.17–1.77, p = 0.0006) and VAF (HR 2.6, 95% CI 1.36–4.93, p = 0.0039) were associated with risk of death; higher T0 cfDNA (HR 1.29, 95% CI 1.08–1.54, p = 0.0049), TF (HR 1.97, 95% CI 1.02–3.82, p = 0.044) and VAF (HR 2.32, 95% CI 1.22–4.42, p = 0.01) were predictors of risk of PD. Among the dynamic changes in the biomarkers under investigation, the association of 10-unit increase of VAF T0-T1 and T0-T2 with OS (HR 1.38, 95% CI 1.01–1.88, p = 0.043; HR 1.56, 95% CI 1.21–2.16, p = 0.008) and PFS (HR 1.69, 95% CI 1.18–2.43, p = 0.004; HR 1.81, 95% CI 1.22–2.70, p = 0.003) was estimated.

Conclusion

T0 and dynamic changes of cfDNA, TF and VAF may help physicians to stratify ES-SCLC patients receiving first-line ACE and to anticipate the clinical course of the disease.